---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-043425"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2026-04-15T23:59:59+00:00"
generated_at: "2026-05-15T06:10:34.027541+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics appoints Matthew Lang as COO and General Counsel

## Summary
- Lang effective April 15, 2026; salary $560,000/yr with 40% target bonus.
- Equity grant: options for 223,776 ordinary shares (74,592 ADSs), time-based RSUs for 184,614 ordinary shares, and PSUs for 46,155 ordinary shares at target.
- Former Chief Legal Officer at Metsera, where he helped guide the up to $10B Pfizer acquisition; also held exec roles at Lyell, Myovant, and Gilead.
- Company advancing aleniglipron into Phase 3 for obesity; Lang to support operational foundation and strategic priorities.

## SEC filing metadata
- accession: 0001104659-26-043425
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2026-04-15T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465926043425/0001104659-26-043425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465926043425/tm2611763d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-043425
- JSON: https://secwatch.observer/filing/0001104659-26-043425.json
- Plain text: https://secwatch.observer/filing/0001104659-26-043425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.